SE9103183L - Virus-antikroppskomplex - Google Patents

Virus-antikroppskomplex

Info

Publication number
SE9103183L
SE9103183L SE9103183A SE9103183A SE9103183L SE 9103183 L SE9103183 L SE 9103183L SE 9103183 A SE9103183 A SE 9103183A SE 9103183 A SE9103183 A SE 9103183A SE 9103183 L SE9103183 L SE 9103183L
Authority
SE
Sweden
Prior art keywords
virus
pct
antibody
date
sec
Prior art date
Application number
SE9103183A
Other languages
Unknown language ( )
English (en)
Other versions
SE9103183D0 (sv
SE503225C2 (sv
Inventor
L Lindholm
S Enerbaeck
Oe Strannegaard
Original Assignee
Leif Lindholm Konsult Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20384166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9103183(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Leif Lindholm Konsult Ab filed Critical Leif Lindholm Konsult Ab
Priority to SE9103183A priority Critical patent/SE503225C2/sv
Publication of SE9103183D0 publication Critical patent/SE9103183D0/sv
Priority to JP5508351A priority patent/JPH07502026A/ja
Priority to DE69232782T priority patent/DE69232782T2/de
Priority to ES92922980T priority patent/ES2180538T3/es
Priority to AT92922980T priority patent/ATE224442T1/de
Priority to PCT/SE1992/000745 priority patent/WO1993009221A1/en
Priority to EP92922980A priority patent/EP0614486B1/en
Priority to CA002122613A priority patent/CA2122613C/en
Priority to US08/232,028 priority patent/US5695991A/en
Publication of SE9103183L publication Critical patent/SE9103183L/sv
Publication of SE503225C2 publication Critical patent/SE503225C2/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SE9103183A 1991-10-30 1991-10-30 Virus-antikroppskomplex för införing av virus i mammalieceller SE503225C2 (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE9103183A SE503225C2 (sv) 1991-10-30 1991-10-30 Virus-antikroppskomplex för införing av virus i mammalieceller
US08/232,028 US5695991A (en) 1991-10-30 1992-10-28 Targeted delivery of virus vector to mammalian cells
CA002122613A CA2122613C (en) 1991-10-30 1992-10-28 Targeted delivery of virus vector to mammalian cells
ES92922980T ES2180538T3 (es) 1991-10-30 1992-10-28 Suministro dirigido de vector virico a celulas de mamiferos.
DE69232782T DE69232782T2 (de) 1991-10-30 1992-10-28 Zielgerichtetes Einbringen eines Virus-Vektors in Säugetierzellen.
JP5508351A JPH07502026A (ja) 1991-10-30 1992-10-28 ウイルス抗体複合体
AT92922980T ATE224442T1 (de) 1991-10-30 1992-10-28 Zielgerichtetes einbringen eines virus-vektors in säugetierzellen.
PCT/SE1992/000745 WO1993009221A1 (en) 1991-10-30 1992-10-28 Targeted delivery of virus vector to mammalian cells
EP92922980A EP0614486B1 (en) 1991-10-30 1992-10-28 Targeted delivery of virus vector to mammalian cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9103183A SE503225C2 (sv) 1991-10-30 1991-10-30 Virus-antikroppskomplex för införing av virus i mammalieceller

Publications (3)

Publication Number Publication Date
SE9103183D0 SE9103183D0 (sv) 1991-10-30
SE9103183L true SE9103183L (sv) 1993-05-01
SE503225C2 SE503225C2 (sv) 1996-04-22

Family

ID=20384166

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9103183A SE503225C2 (sv) 1991-10-30 1991-10-30 Virus-antikroppskomplex för införing av virus i mammalieceller

Country Status (9)

Country Link
US (1) US5695991A (sv)
EP (1) EP0614486B1 (sv)
JP (1) JPH07502026A (sv)
AT (1) ATE224442T1 (sv)
CA (1) CA2122613C (sv)
DE (1) DE69232782T2 (sv)
ES (1) ES2180538T3 (sv)
SE (1) SE503225C2 (sv)
WO (1) WO1993009221A1 (sv)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE503225C2 (sv) * 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
DE4311651A1 (de) * 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5753499A (en) * 1994-12-23 1998-05-19 New York University Viral vector complexes having adapters of predefined valence
US5770442A (en) 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
US6127525A (en) * 1995-02-21 2000-10-03 Cornell Research Foundation, Inc. Chimeric adenoviral coat protein and methods of using same
WO1997005266A1 (en) 1995-07-25 1997-02-13 Introgene B.V. Methods and means for targeted gene delivery
US6472204B1 (en) 1995-11-13 2002-10-29 Kiyozo Asada Methods for retroviral mediated gene transfer employing molecules, or mixtures thereof, containing retroviral binding domains and target cell binding domains
DE19605279A1 (de) 1996-02-13 1997-08-14 Hoechst Ag Zielzellspezifische Vektoren für die Einschleusung von Genen in Zellen, Arzneimittel enthaltend derartige Vektoren und deren Verwendung
EP0927044A4 (en) * 1996-04-16 1999-09-08 Immusol Inc DEFINED TARGET VIRAL VECTORS
US20060002949A1 (en) 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
DE19649645A1 (de) * 1996-11-29 1998-06-04 Hoechst Ag Mehrfach funktionelles Ligandensystem zur zielzellspezifischen Übertragung von Nukleotidsequenzen
US6432699B1 (en) 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
AU737727B2 (en) 1997-04-10 2001-08-30 University Of Southern California Modified viral surface proteins for binding to extracellular matrix components
AU7127798A (en) * 1997-04-18 1998-11-13 President And Fellows Of Harvard College Bifunctional polypeptides for cell-specific viral targeting
US6004798A (en) * 1997-05-14 1999-12-21 University Of Southern California Retroviral envelopes having modified hypervariable polyproline regions
US6287857B1 (en) 1998-02-09 2001-09-11 Genzyme Corporation Nucleic acid delivery vehicles
AU2662999A (en) * 1998-02-09 1999-08-23 Genzyme Corporation Nucleic acid delivery vehicles
US7078483B2 (en) * 1998-04-29 2006-07-18 University Of Southern California Retroviral vectors including modified envelope escort proteins
US20060292121A1 (en) * 1998-04-29 2006-12-28 Hall Frederick L Retroviral vectors including modified envelope escort protein
WO1999055365A1 (en) 1998-04-30 1999-11-04 Cornell Research Foundation, Inc. Adenoviral vectors with tandem fiber proteins
US6060316A (en) * 1998-06-09 2000-05-09 President And Fellows Of Harvard College Methods of targeting of viral entry
CA2342396A1 (en) 1998-09-11 2000-03-23 Genvec, Inc. Alternatively targeted adenovirus
AUPQ425699A0 (en) 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
EP1301612A2 (en) * 2000-05-31 2003-04-16 Genvec, Inc. Method and composition for targeting an adenoviral vector
AU2002953436A0 (en) 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US11266736B2 (en) 2008-04-17 2022-03-08 Vin De Bona Trading Company Pte Ltd Method of painting micro vesicles
EP2281033B1 (en) 2008-04-17 2014-10-15 Vin de Bona Trading Co Pte Post release modification of viral envelopes
CN110418650A (zh) 2016-11-16 2019-11-05 免疫治疗有限公司 用于治疗过敏的核酸
US11203629B2 (en) 2017-04-22 2021-12-21 Immunomic Therapeutics, Inc. LAMP constructs
WO2018204534A1 (en) 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
WO2019222281A1 (en) 2018-05-15 2019-11-21 Immunomic Therapeutics, Inc Improved lamp constructs comprising allergens
EP4045528A1 (en) 2019-10-18 2022-08-24 Immunomic Therapeutics, Inc. Improved lamp constructs comprising cancer antigens
WO2023201201A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364934A (en) * 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human early thymocyte antigen and methods for preparing same
US5428132A (en) * 1987-10-11 1995-06-27 United States Of America Conjugate and method for integration of foreign DNA into cells
JP2917998B2 (ja) * 1988-02-05 1999-07-12 ホワイトヘッド・インスティチュート・フォー・バイオメディカル・リサーチ 修飾された肝細胞およびその用途
WO1990012087A1 (en) * 1989-04-05 1990-10-18 Novacell Corporation Infectious targetted replication-defective virion
FR2649119A1 (fr) * 1989-06-30 1991-01-04 Centre Nat Rech Scient Procede de pilotage de retrovirus en utilisant des complexes bifonctionnels
EP0487587A1 (en) * 1989-08-18 1992-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
WO1991004753A1 (en) * 1989-10-02 1991-04-18 Cetus Corporation Conjugates of antisense oligonucleotides and therapeutic uses thereof
AU660629B2 (en) * 1990-10-01 1995-07-06 University Of Connecticut, The Targeting viruses and cells for selective internalization by cells
SE503225C2 (sv) * 1991-10-30 1996-04-22 Leif Lindholm Konsult Ab Virus-antikroppskomplex för införing av virus i mammalieceller

Also Published As

Publication number Publication date
US5695991A (en) 1997-12-09
CA2122613A1 (en) 1993-05-13
JPH07502026A (ja) 1995-03-02
ES2180538T3 (es) 2003-02-16
EP0614486A1 (en) 1994-09-14
EP0614486B1 (en) 2002-09-18
DE69232782T2 (de) 2003-02-20
SE9103183D0 (sv) 1991-10-30
ATE224442T1 (de) 2002-10-15
WO1993009221A1 (en) 1993-05-13
SE503225C2 (sv) 1996-04-22
DE69232782D1 (de) 2002-10-24
CA2122613C (en) 2003-08-19

Similar Documents

Publication Publication Date Title
SE9103183L (sv) Virus-antikroppskomplex
MY104946A (en) Antigen antibody conjugate.
NO883981L (no) Fast katalysatorkomponent for olefinkopolymerisasjon og fremgangsmaate for olefinkopolymerisasjon ved anvendelse av nevnte faste katalysatorkomponent.
IL88248A (en) Solid phase immunoassay for detecting hiv antigens using kc-57 monoclonal antibody, and kit for the performance thereof
EP0956304A4 (en) SPECIFIC ANTIBODIES FOR DENDRITIC CELLS
TR199701545T1 (xx) Yeni dolastatin t�revleri,haz�rlanmalar� ve kullan�mlar�
PT649537E (pt) Imunoanalises para anticorpos anti-vhc utilizando antigenios com epitopos conformacionais
FI932912A (fi) Testmetod och reagensfoerpackning avsedd foer den
DE69021953D1 (de) Enzymimmuntest für Antigene und dafür verwendbare feste Phase.
ES2176347T3 (es) Modulacion de la respuesta inmune.
NO884368D0 (no) Immunobestemmelse under anvendelse av iggoppfangningsantigen, og multippel antistoffpaavisningssystem.
DE60017019D1 (de) Antikörper gegen Spaltprodukte von Vimentin
TR26973A (tr) Bacillus thuringiensis cryie geni ve lepidoptera takimindan böceklere karsi zehirli protein.
DE3882727T2 (de) Mycoplasma-Membran-Antigene und ihre Verwendung.
DE69130845D1 (de) HLA-DR Antigen-Gen, dessen Nukleotidsequenz und Verwendung
EP0293827A3 (en) Assay for leishmaniasis
DE3888887D1 (de) Monoklonale Antikörper gegen E7-Protein des Humanen Papillomvirus Typ 16, Verfahren zu ihrer Herstellung sowie ihre Verwendung.
DE3482924D1 (de) Reagenz zur verwendung im nachweis des antikoerpers gegen menschliche t-zellen-leukemievirusantigene.
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
MY100476A (en) Supported viral antigen and preparation and use thereof
ATE51894T1 (de) Spezifische mycoplasma-membran-antigene und antik¯rper sowie deren klinische verwendungen.
ATE39054T1 (de) Dns viren-vakzin.
EP0342422A3 (en) Process for the preparation of 2',3'-dideoxynucleosides, and intermediates used therein
DK0650523T3 (da) Rekombinant CDw52-antigen
Hino Experimental infection of C. psittaci (MP) strain in mice--evaluation of changes in the histopathological findings in lungs and serum antibodies in mice intranasally inoculated with C. psittaci, and comparison with histopathological findings in organs in mice inoculated by various routes of infection

Legal Events

Date Code Title Description
NUG Patent has lapsed